Senti Biosciences, Inc. (SNTI) Stock Score, Valuation & Financial Research
Senti Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for SNTI
Senti Biosciences, Inc. currently has a Wall Street Score of 16/100. The stored market price is $0.31. Its financial score is 3/100. Its valuation score is 0/100. The latest WSS change is +3.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Senti Biosciences, Inc. does
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marr
SNTI financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $0.31
- Market capitalization:
- $9.7M
- Revenue:
- $55K
- Net income:
- $-49.6M
- Free cash flow:
- $-43.6M
- Cash:
- $6.5M
- Total debt:
- $20.2M
- EPS:
- -1.77
- Financial score:
- 3/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +1.5%.
- Free cash flow is $-43.6M, showing cash burn in the current stored period.
- The balance sheet shows $6.5M of cash versus $20.2M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +3.1 points: SNTI increased 3.1 points because Management improved by 33.3 points, Buffett improved by 4.6 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 3/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research SNTI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.